In Silico Preclinical Trials: A Proof of Concept in Closed-Loop Control of Type 1 Diabetes

Доклинические испытания in silico: доказательство концепции замкнутого управления сахарным диабетом 1 типа
Boris P. Kovatchev, Marc D. Breton, Chiara Dalla Man, Claudio Cobelli
2009-01-01

artificial pancreasclosed-loop controlcontinuous glucose monitoringin silico preclinical trialstype 1 diabetes mellitus
Arguably, a minimally invasive system using subcutaneous (s.c.) continuous glucose monitoring (CGM) and s.c. insulin delivery via insulin pump would be a most feasible step to closed-loop control in type 1 diabetes mellitus (T1DM). Consequently, diabetes technology is focusing on developing an artificial pancreas using control algorithms to link CGM with s.c. insulin delivery. The future development of the artificial pancreas will be greatly accelerated by employing mathematical modeling and computer simulation. Realistic computer simulation is capable of providing invaluable information about the safety and the limitations of closed-loop control algorithms, guiding clinical studies, and out-ruling ineffective control scenarios in a cost-effective manner. Thus computer simulation testing of closed-loop control algorithms is regarded as a prerequisite to clinical trials of the artificial pancreas. In this paper, we present a system for in silico testing of control algorithms that has three principal components: (1) a large cohort of n=300 simulated "subjects" (n=100 adults, 100 adolescents, and 100 children) based on real individuals' data and spanning the observed variability of key metabolic parameters in the general population of people with T1DM; (2) a simulator of CGM sensor errors representative of Freestyle Navigator™, Guardian RT, or Dexcom™ STS™, 7-day sensor; and (3) a simulator of discrete s.c. insulin delivery via OmniPod Insulin Management System or Deltec Cozmo(®) insulin pump. The system has been shown to represent adequate glucose fluctuations in T1DM observed during meal challenges, and has been accepted by the Food and Drug Administration as a substitute to animal trials in the preclinical testing of closed-loop control strategies.
1
A three-component in silico testing system was developed for preclinical evaluation of closed-loop artificial-pancreas control algorithms.
2
It simulates discrete subcutaneous insulin delivery using OmniPod or Deltec Cozmo insulin pumps.
3
The simulator reproduced glucose fluctuations observed during type 1 diabetes meal challenges and was accepted by the FDA as an alternative to animal trials for preclinical closed-loop testing.
4
The system simulates continuous glucose-monitoring errors characteristic of Freestyle Navigator, Guardian RT, and Dexcom STS 7-day sensors.
5
The virtual cohort includes 300 simulated people with type 1 diabetes: 100 adults, 100 adolescents, and 100 children, representing population variability in metabolic parameters.

In silico artificial-pancreas system for closed-loop control of type 1 diabetes mellitus, comprising simulated T1DM subjects, CGM sensor-error simulation, and subcutaneous insulin-delivery simulation

Preclinical safety and performance assessment of closed-loop control algorithms under realistic interindividual metabolic variability, CGM sensor errors, and discrete subcutaneous insulin delivery

Publication Details
Publication Date
2009-01-01
Journal
Journal of Diabetes Science and Technology
Publisher
SAGE Publishing
ISSN
1932-2968
Cited by
872
Access Type
Author Information
Authors
Boris P. Kovatchev
Marc D. Breton
Chiara Dalla Man
Claudio Cobelli
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%